21 results about "Fenofibrate" patented technology

The invention discloses a gelatin-hyaluronic acid injectable hydrogel drug-carrying nanoparticle composite material as well as a preparation method and application thereof, relates to the technical field of biomedicine, and solves the problems that in the prior art, existing drugs for treating cartilage related diseases are difficult to deliver; the chronic inflammatory response in the articular cavity cannot be effectively controlled and cartilage cells cannot be protected at the same time, so that the application effect of the medicine is limited. The preparation method disclosed by the invention comprises the following steps: S1, obtaining a carnosine modified hyaluronic acid derivative Car-HA; s2, preparing nano particles (FNPs) loaded with fenofibrate; and S3, mixing the gelatin solution containing the FNPs with a Car-HA solution, adding transglutaminase into the mixed system, and carrying out an enzymatic cross-linking reaction to form the hydrogel FNPs-GelHA with a stable network structure. The CarHA and FNPs synergistic hydrogel strategy provided by the invention has good structural adjustability and drug adaptability, is suitable for delivery of various anti-inflammatory, anti-oxidation and cartilage repair drugs, and can be widely applied to local precise treatment of cartilage related diseases.

A method of producing a fenofibrate composition having a higher dissolution rate in an aqueous medium, the method comprising mixing fenofibrate in an organic solvent solution with an organic acid and other excipients to produce a composition in the form of granules, tablets or capsules.

The present application relates to the technical field of pharmaceutical chemistry, and particularly relates to a preparation method of fenofibrate and impurities thereof. The present application carries out Friedel-Crafts acylation reaction on 4-chlorobenzoyl chloride, anisole, Lewis acid and benzene solvent, then carries out demethylation reaction, and then separates and purifies to obtain compound II, impurity compound IV and impurity compound V; the compound II (or impurity compound IV), 2-bromoisobutyric acid isopropyl ester, an alkaline reagent and an alcohol solvent are mixed to carry out etherification reaction, and then separated and purified to obtain fenofibrate (or impurity compound VI). The preparation method provided by the present application has high yield and high purity of fenofibrate, can realize identification of impurities in the preparation process of fenofibrate, and provides a convenient condition for quality control of bulk drug. Moreover, the raw materials and solvents used are widely sourced, low in cost and small in danger, the preparation method is high in safety factor, simple in operation, and suitable for large-scale industrial production.

A fenofibrate composition comprising water soluble chemicals, the composition having a higher dissolution rate in an aqueous medium, wherein the composition is prepared by mixing fenofibrate in an organic solvent solution with an organic acid and other excipients to produce the composition in the form of granules, a tablet or a capsule.

The present invention relates to the field of biomedical technologies, and particularly to the application of fenofibrate in the treatment of Fuchs endothelial corneal dystrophy. By using the fenofibrate drug, the present invention can effectively reduce the thickness of Descemet's membrane during the pathogenesis of FECD, reduce the decrease in corneal endothelial cell density, cell damage, etc., and ultimately improve corneal endothelial decompensation.

The invention relates to an anti-inflammatory and lipid-lowering-based nano preparation for treating fatty liver and a preparation method of the nano preparation. Galactose modified polyethylene glycol-polylactic acid-glycolic acid copolymer (PEG-PLGA) is used as a targeting carrier, and a lipid-lowering drug fenofibrate and an anti-inflammatory drug curcumin are co-loaded; the particle size of the nano preparation is 150-200nm, and the drug encapsulation efficiency is greater than or equal to 85%. Galactose modified PEG-PLGA is adopted as a carrier, galactose can be specifically combined with an asialoglycoprotein receptor (ASGPR) specifically expressed on the surface of liver cells, active targeting of the liver is achieved, the drug enrichment amount of the liver lesion position is remarkably increased, meanwhile, accumulation of drugs in extrahepatic tissue is reduced, extrahepatic toxicity is effectively reduced, and the drug delivery effect is improved. According to the present invention, the anti-inflammatory drug curcumin and the fenofibrate are combined, such that the biological safety of the preparation is improved, the lipid lowering drug fenofibrate and the anti-inflammatory drug curcumin are innovatively co-loaded, and the fenofibrate and the anti-inflammatory drug curcumin form the synergistic effect system: fenofibrate can activate peroxisome proliferator-activated receptor alpha (PPAR alpha), promote liver lipid catabolism, and reduce lipid deposition;

The invention belongs to the technical field of drug crystallization, and provides metformin hydrochloride and fenofibrate double-drug-loading particles and a preparation method thereof.The preparation method comprises the following steps that polysaccharide, a solvent I and metformin hydrochloride are mixed and heated, and a homogeneous solution is obtained; mixing the homogeneous solution, fenofibrate and triglyceride to obtain a suspension; a cross-linking agent, a solvent II and the suspension are mixed and placed in a crystallizer to be subjected to a crystallization reaction, and a crystallization solution is obtained; and carrying out solid-liquid separation on the crystallization liquid, washing, and drying to obtain the double-drug-loading particles. The obtained particles are in a solid state and have good stability compared with a micelle drug loading system, meanwhile, the operation unit is simplified by adopting an in-situ crystallization means in the carrier, operation such as mixing, grinding and spray drying is not needed, needed equipment is simple, operation is easy and convenient, and good technical economy and high application value are achieved.

The invention provides a composition and method of treating depression by administering to a patient in need of such treatment a combination of pindolol and fenofibrate in a ratio of about 3mg pindolol / 33mg fenofibrate and is useful in augmentation to treatment of depression.

The invention provides a double-layer tablet containing ezetimibe and fenofibrate. The double-layer tablet comprises an ezetimibe quick release layer and a fenofibrate slow release layer, the ezetimibe quick-release layer comprises ezetimibe, a quick-release layer filler, a quick-release layer surfactant, a quick-release layer adhesive, a quick-release layer disintegrating agent and a quick-release layer lubricant; the fenofibrate sustained-release layer comprises fenofibrate, a sustained-release layer filler, a sustained-release layer disintegrating agent, a sustained-release layer adhesive, a sustained-release layer solubilizer, a sustained-release layer sustained-release framework material and a sustained-release layer lubricant. The invention also provides a preparation method of the double-layer tablet. The double-layer tablet provided by the invention can be used for clinical treatment of hypercholesterolemia, hypertriglyceridemia and mixed dyslipidemia, the levels of triglyceride, total cholesterol and LDL-C are comprehensively reduced, the level of HDL-C is increased, and the occurrence rate of adverse reactions is relatively low.

The invention discloses a dihydrochalcone glucoside compound with the following structural formula, which is separated from malus toringoides, a high-fat model is obtained by inducing HepG2 cells through oleic acid, and the dihydrochalcone glucoside compound is used for treating the high-fat model, so that the dihydrochalcone glucoside compound is obtained. Experimental results show that the dihydrochalcone glycoside compound can effectively down-regulate accumulation of TG in human hepatoma cells (HepG2) treated by oleic acid at low concentration and reduce the number of lipid droplets, the effect is better than that of a positive drug fenofibrate, and the results show that the dihydrochalcone glycoside compound has a lipid-lowering effect and can be used for treating liver cancer cells (HepG2). The invention provides a new way for developing high-efficiency and low-toxicity lipid-lowering products; # imgabs0 #

The invention provides a pharmaceutical composition for reprogramming repair type macrophages and a reprogramming method thereof, the pharmaceutical composition comprises four micromolecular drugs of fenofibrate, dexamethasone, rosaxostat and calcitriol, and the four micromolecular drugs FDRC are combined in a certain dosage and applied to the macrophages to reprogram the macrophages with repair function phenotypes. The macrophages are reprogrammed into a repair-promoting functional phenotype, and the macrophages can promote the proliferation and repair effects of epithelial cells and vascular endothelial cells by secreting a large number of repair factors, such as Vegfa, Gdf15, Hbegf, Ndrg1, Tamp3, Ccn1 and the like.

The invention discloses application of fenofibrate to improvement of learning and memory ability decline caused by a microgravity effect. Experiments show that fenofibrate can effectively improve the reduction of the spatial memory ability of a mouse with a suspended tail. Experimental results show that fenofibrate has the value of being developed into drugs for preventing and treating related learning and memory ability decline.

The invention belongs to the technical field of pharmaceutical preparations, and relates to fenofibrate tablets and a preparation process thereof. According to the fenofibrate tablet, through the synergistic effect of the composite solubilizing stabilizer and the optimized preparation process, the drug dissolution efficiency and the preparation stability are effectively improved, meanwhile, the preparation process does not need special equipment, the steps are clear and controllable, the production difficulty and cost are reduced on the premise that the preparation performance is guaranteed, and the fenofibrate tablet is suitable for industrial production and has a wide application prospect. And the method has important significance for promoting industrial upgrading and clinical application of fenofibrate preparations.

The invention discloses application of fenofibrate in preparation of a medicine for preventing obesity or renal ischemia-reperfusion injury aggravated by high fat diet induction, and relates to the technical field of medicines. The invention relates to an application of fenofibrate in preparation of a medicine for preventing renal ischemia reperfusion injury aggravated by obesity or high fat diet induction. The prophylaxis potential of fenofibrate is verified in an obesity and common mouse renal ischemia reperfusion injury (IRI) model for the first time, and a means for effectively inhibiting obesity-induced injury aggravation is lacked in the treatment of kidney IRI at present, especially under the background of high fat diet or metabolic stress. The fenofibrate relieves injury aggravation caused by high fat / obesity, and a new preventive drug choice is provided for the field. According to the invention, a preventive scheme of starting administration in advance is adopted, which shows that intervention of fenofibrate on the early stage of IRI occurrence also can effectively reduce the risk of subsequent injury, which has a reference value for'preoperative administration 'or'intervention of obese high-risk patients' in clinic.

The invention discloses application of a dimeric dihydrochalcone compound in preparation of a lipid-lowering product, which is characterized in that HepG2 cells are induced by oleic acid to obtain a high-lipid model, and the high-lipid model is treated by the dimeric dihydrochalcone compound to obtain the lipid-lowering product. Experimental results show that the dimeric dihydrochalcone compound can effectively down-regulate accumulation of TG in HepG2 cells treated by oleic acid at low concentration and reduce the number of lipid droplets, the effect of the dimeric dihydrochalcone compound is superior to that of a positive drug fenofibrate, and the result shows that the dimeric dihydrochalcone compound has a lipid-lowering effect and can be used for preparing a novel anti-tumor drug. The invention provides a new way for developing high-efficiency and low-toxicity lipid-lowering products.

The invention discloses a fenofibrate-containing pharmaceutical composition, which is characterized in that the fenofibrate-containing pharmaceutical composition comprises fenofibrate, a filler, a disintegrating agent, a lubricant, an adhesive and a surfactant, the surfactant is teloxpol, the disintegrating agent adopts an internal and external addition method in the preparation process, and the lubricant adopts an internal and external addition method in the preparation process. By internally and externally adding the disintegrating agent and the lubricating agent, the defects of particle aggregation, dissolution speed reduction, poor stability and the like can be specifically solved, and under the condition of micronization of the fenofibrate raw material, rapid dissolution, high bioavailability and stability of the fenofibrate capsule can be ensured at the same time.

This invention belongs to the field of pharmaceutical technology and discloses a pharmaceutical composition of a USP7 inhibitor and fenofibrate and its antitumor application. The pharmaceutical composition uses a USP7 inhibitor and fenofibrate as the core active ingredients, with a molar ratio of 0.015625 to 0.625. The USP7 inhibitor is selected from at least one of LX04-104 and LML-17-133. This invention is the first to discover that fenofibrate can significantly enhance the antitumor effect of the USP7 inhibitor, and the combination of the two has a synergistic effect. This synergistic effect is cell type specific, particularly significant for nasopharyngeal carcinoma and pancreatic cancer, and the synergistic effect of fenofibrate is independent of the PPARα pathway. This composition can be prepared as an oral or injectable formulation for the treatment of nasopharyngeal carcinoma and pancreatic cancer, and has good prospects for clinical translation.

The invention relates to a fenofibrate nano eutectic composition and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The fenofibrate nano eutectic composition is composed of fenofibrate, a eutectic forming agent, a stabilizer, a filler, a flow aid and a lubricant. The specific method comprises the following steps: forming a fenofibrate eutectic from fenofibrate and a eutectic forming agent, and performing nanocrystallization through a medium grinding method so as to improve the solubility and the dissolution rate of an indissolvable bulk drug; forming a nano suspension from the nano-crystallized eutectic, a stabilizer and water, and freeze-drying to obtain stable nano eutectic particles; and uniformly mixing with other auxiliary materials, and filling into capsules or pressing into tablets. Compared with an original drug, the dissolution rate and bioavailability of the tablet are increased.

The invention relates to the technical field of biological medicines, and provides application of a PPARalpha (peroxisome proliferator activated receptor alpha) agonist, namely fenofibrate Feyfibrate, Wy14643 and PEA (peroxisome proliferator activated receptor alpha). The PPARalpha agonists Fenofirate, Wy14643 and PEA provided by the invention can be directly or indirectly combined with PPARalpha protein through specificity and activate the activity of the PPARalpha protein, so that a PPARalpha signal channel is regulated, and diarrhea reaction after stimulation of new coronavirus is relieved. The Fenofibrate, the Wy14643 and the PEA disclosed by the invention are high in treatment specificity, small in side effect and good in effect when being used for treating new coronavirus infection.